表紙
市場調査レポート

SK Biopharmaceuticals Co., Ltd. :製品パイプライン分析

SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 251723
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
SK Biopharmaceuticals Co., Ltd. :製品パイプライン分析 SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2016
出版日: 2016年03月31日 ページ情報: 英文 49 Pages
概要

SK Biopharmaceuticals Co., Ltd.は、中枢神経系疾患の新たな治療薬を開発している製薬会社で、その製品は主にてんかん、不安神経症、鬱病、統合失調症、パーキンソン病、過敏性腸症候群、そして糖尿病などの治療に使われています。

当レポートでは、SK Biopharmaceuticals Co., Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

SK Biopharmaceuticals Co., Ltd.の基本情報

  • SK Biopharmaceuticals Co., Ltd.の概要
  • 主要情報
  • 企業情報

SK Biopharmaceuticals Co., Ltd.:R&Dの概要

  • 主な治療範囲

SK Biopharmaceuticals Co., Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

SK Biopharmaceuticals Co., Ltd.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • IND/CTA に申請された製品/併用療法モダリティ
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

SK Biopharmaceuticals Co., Ltd.:薬剤プロファイル

  • SKL-N05
  • YKP-3089
  • relenopride hydrochloride
  • carisbamate
  • SKL-15508
  • SKL-A4R
  • SKL-PD
  • SKL-PSY
  • N-2
  • SKL-16036
  • SKL-G
  • 多発性硬化症治療用小分子
  • 神経因性疼痛治療用小分子
  • タウオパシー、アルツハイマー病治療用小分子
  • 筋萎縮性側索硬化症用 TDP-43 阻害小分子

SK Biopharmaceuticals Co., Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

SK Biopharmaceuticals Co., Ltd.:最近のパイプライン動向

SK Biopharmaceuticals Co., Ltd.:休止中のプロジェクト

SK Biopharmaceuticals Co., Ltd.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • carisbamate

SK Biopharmaceuticals Co., Ltd.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08018CDB

Summary

Global Markets Direct's, 'SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the SK Biopharmaceuticals Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by SK Biopharmaceuticals Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of SK Biopharmaceuticals Co., Ltd.
  • The report provides overview of SK Biopharmaceuticals Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses SK Biopharmaceuticals Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features SK Biopharmaceuticals Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate SK Biopharmaceuticals Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for SK Biopharmaceuticals Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding SK Biopharmaceuticals Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • SK Biopharmaceuticals Co., Ltd. Snapshot
    • SK Biopharmaceuticals Co., Ltd. Overview
    • Key Information
    • Key Facts
  • SK Biopharmaceuticals Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Products Glance
    • SK Biopharmaceuticals Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • SK Biopharmaceuticals Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • SK Biopharmaceuticals Co., Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • SK Biopharmaceuticals Co., Ltd. - Drug Profiles
    • SKL-N05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YKP-3089
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • relenopride hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carisbamate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-15508
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-A4R
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-PD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-PSY
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • N-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-16036
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-DEP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-G
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Tauopathies and Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Analysis
    • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Target
    • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Route of Administration
    • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Molecule Type
    • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action
  • SK Biopharmaceuticals Co., Ltd. - Recent Pipeline Updates
  • SK Biopharmaceuticals Co., Ltd. - Dormant Projects
  • SK Biopharmaceuticals Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • carisbamate
  • SK Biopharmaceuticals Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • SK Biopharmaceuticals Co., Ltd., Key Information
  • SK Biopharmaceuticals Co., Ltd., Key Facts
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Indication, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2016
  • SK Biopharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • SK Biopharmaceuticals Co., Ltd. - Phase III, 2016
  • SK Biopharmaceuticals Co., Ltd. - Phase II, 2016
  • SK Biopharmaceuticals Co., Ltd. - Phase I, 2016
  • SK Biopharmaceuticals Co., Ltd. - IND/CTA Filed, 2016
  • SK Biopharmaceuticals Co., Ltd. - Preclinical, 2016
  • SK Biopharmaceuticals Co., Ltd. - Discovery, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Target, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Route of Administration, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Molecule Type, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • SK Biopharmaceuticals Co., Ltd. - Recent Pipeline Updates, 2016
  • SK Biopharmaceuticals Co., Ltd. - Dormant Developmental Projects,2016
  • SK Biopharmaceuticals Co., Ltd. - Discontinued Pipeline Products, 2016
  • SK Biopharmaceuticals Co., Ltd., Other Locations
  • SK Biopharmaceuticals Co., Ltd., Subsidiaries

List of Figures

  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2016
  • SK Biopharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Top 10 Target, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Route of Administration, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline by Molecule Type, 2016
  • SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top